.Vogel® Supports Canadian Communities with Proactive Programs During COVID-19
Quebec-based company prioritizes investment in research, donations to local food banks, and increasing employee wages.
MONTREAL, May 13, 2020 /CNW/ - A.Vogel® recognizes the need for charitable giving and innovative research during the COVID-19 pandemic. The company has launched proactive initiatives including investing in Canadian-based emergency COVID-19 research, matching donations for charitable giving, donating to food banks, supporting front-line employees with increased wages and access to personal protective equipment and encouraging remote work.
"Reinvesting in research and seeking solutions to Canadian health and wellness needs is an important mission at A.Vogel®," says Mackie Vadacchino, CEO at A.Vogel® Canada. "We are one community and are trying to lead by example to inspire positive action in Canada. We have donated $100,000 to the McGill Interdisciplinary Initiative in Infection and Immunity (MI4), which brings together 5,000 medical staff and 250 experts in infectious and immune diseases, all actively working to reduce the threat of COVID-19. We are proud to see our donation programs inspire $246,960 in gifts from supporters and community members to date. Together, we can accomplish anything."
To ensure those most vulnerable are protected, A.Vogel® has donated non-perishable food items valued at $50,000 to Moisson Montreal and Moisson Quebec, and contributed $500 to the Canadian College of Naturopathic Medicine, to support the college's student relief fund. A.Vogel® is supporting employees with a 15 per cent wage increase and protecting production-line employees with access to personal protective equipment (PPE) such as masks, gloves and rigorous – frequent – personal hygiene safety measures, and encouraging non-essential personnel to work from home.
The company's global arm is conducting innovative research on Echinaforce – one of its prominent traditional herbal remedy used for the prevention and symptomatic relief of colds and influenza type infections and similar upper respiratory tract conditions – to investigate its benefits on COVID-19. Based on previous scientific data, Echinaforce has proven to be effective in prevention of SARS, MERS, H1N1 and other strains of the Coronavirus1.
A.Vogel® is Canada's leading health brand with a wide range of natural products based in science. It was founded in Basel, Switzerland in 1923 by Swiss pioneer Alfred Vogel and entered the Canadian market in 1956. A.Vogel's commitment to organic farming methods means the company uses its own carefully selected seeds, knowing the history of each plant and having full traceability. The efficacy of A.Vogel's fresh plant preparations has been proven by over 30 clinical studies. Products range from natural pharmaceutical remedies, dietary supplements and food products. To learn more, visit avogel.ca.
|1 Pleschka S, Stein M, Schoop R, Hudson JB: Anti-Viral properties and mode of action of standardized Echinacea Purpurea extract against highly pathogenic avian Influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). Virology Journal (paper accepted November 2009). |
Sharma M, Anderson SA, Schoop R, Hudson JB: Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. Antiviral Res. 2009 Aug;83(2):165-70 (http://dx.doi.org/10.1016/j.antiviral.2009.04.009)